Nature of Business (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) segment	Jun. 30, 2021 USD ($)	Aug. 05, 2022 USD ($)	Dec. 31, 2021 USD ($)	Aug. 13, 2021 USD ($)	Dec. 31, 2020 USD ($)
Nature of business:
Number of operating segments | segment			2
Accumulated deficit	$ (212,500,888)		$ (212,500,888)			$ (205,765,107)
Net loss	(2,386,760)	$ (1,897,068)	(6,735,781)	$ (4,259,546)
Net cash used in operating activities			(5,766,903)	(5,644,147)
Cash and cash equivalents	20,157,692	$ 28,979,969	20,157,692	28,979,969		26,043,897		$ 18,676,663
Net decrease in cash			$ 5,886,205	$ (10,303,306)
Percentage change in cash and cash equivalent			(23.00%)
Working capital	11,985,310		$ 11,985,310			20,278,345
Working capital increase, decrease			$ (8,293,035)
Working capital increase (decrease) as a percent			(41.00%)
Government grant funding	321,779		$ 321,779			$ 138,889
Common Stock, Value, Subscriptions							$ 30,000,000
Subsequent Event [Member]
Nature of business:
Common Stock, Value, Subscriptions					$ 26,800,000
CiVax
Nature of business:
Revenue from collaborative arrangement			$ 1,500,000
Term (in years)			two years
NIH
Nature of business:
Government grant funding	$ 1,000,000.0		$ 1,000,000.0
NIAID | Contract revenue
Nature of business:
Revenue from collaborative arrangement			$ 700,000
Term (in years)			five years
DTRA | Contract revenue
Nature of business:
Revenue from collaborative arrangement			$ 600,000
Term (in years)			three years